| 000 | 01655 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250513233328.0 | ||
| 264 | 0 | _c20010705 | |
| 008 | 200107s 0 0 eng d | ||
| 022 | _a0301-0147 | ||
| 024 | 7 |
_a10.1159/000054166 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGallus, A S | |
| 245 | 0 | 0 |
_aPreventing venous thromboembolism in general medical inpatients and after an ischaemic stroke. _h[electronic resource] |
| 260 |
_bHaemostasis _c2000 |
||
| 300 |
_a64-71; discussion 63 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAcute Disease |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnticoagulants _xadministration & dosage |
| 650 | 0 | 4 |
_aBrain Ischemia _xcomplications |
| 650 | 0 | 4 |
_aCerebral Hemorrhage _xchemically induced |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aEnoxaparin _xadministration & dosage |
| 650 | 0 | 4 |
_aHeparin _xadministration & dosage |
| 650 | 0 | 4 |
_aHeparin, Low-Molecular-Weight _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInpatients |
| 650 | 0 | 4 | _aLaser-Doppler Flowmetry |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 | _aPhlebography |
| 650 | 0 | 4 | _aPlethysmography |
| 650 | 0 | 4 |
_aPulmonary Embolism _xetiology |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aRisk |
| 650 | 0 | 4 |
_aThromboembolism _xetiology |
| 650 | 0 | 4 |
_aThrombophlebitis _xdiagnosis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 773 | 0 |
_tHaemostasis _gvol. 30 Suppl 2 _gp. 64-71; discussion 63 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1159/000054166 _zAvailable from publisher's website |
| 999 |
_c11188120 _d11188120 |
||